Tavexia Lifecare Limited’s Board of Directors has approved a proposal for raising funds up to ₹68 crore. This fundraising effort is intended to finance the proposed acquisition of 60% of the equity share capital of Meyonex Pharmaceuticals Limited. The board also approved the un-audited financial results for the quarter and half-year ended September 30, 2026, and decided to change the company’s Registrar and Transfer Agent.
Tavexia Lifecare Board Approves Key Financials and Strategic Moves
The Board of Directors of Tavexia Lifecare Limited convened on Wednesday, November 4, 2026, to discuss and approve several critical business matters. The meeting resulted in the approval of the un-audited financial results, both standalone and consolidated, for the quarter and half-year ended September 30, 2026. A Limited Review Report from M/s DEVAM & Associates LLP was also taken on record.
Significant Fundraise for Acquisition
A major highlight of the board meeting was the in-principle approval for raising funds amounting to up to ₹68,00,00,000 (Rupees Sixty-Eight Crores Only). These funds are earmarked to finance the proposed acquisition of 60% of the equity share capital of Meyonex Pharmaceuticals Limited. The board authorized the Executive Directors to appoint necessary consultants and experts to determine the most appropriate mode and type of securities issuance for this significant fundraising initiative. The final decision on the structure and terms of the fund raising will be considered in a subsequent meeting.
Change in Registrar and Transfer Agent
In a move to enhance operational efficiency, the company also approved the change of its Registrar and Transfer Agent (RTA). The role will transition from Niche Technologies Pvt. Ltd. to Skyline Financial Services Pvt. Ltd. Niche Technologies will continue its services until the completion of data transition and other procedural formalities. Skyline Financial Services was chosen for its technologically advanced infrastructure, promising quick and quality services.
Other Business Decisions
The board also considered and took on record the Statement of deviation(s) or variation(s) in the use of proceeds from the Right Issue offer document, as per Regulation 32 of SEBI (LODR) Regulations, 2015.
Source: BSE
